4d
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ...
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc ("GSK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback